Recent Finacing
Recent Raise
Areteia Therapeutics is a clinical-stage biotech developing dexpramipexole, an oral small-molecule eosinophil maturation inhibitor in Phase III trials for eosinophilic asthma, partnering with Validae Health and expanding manufacturing.
